ArticleCureus2026
Patient-Reported Flare Symptoms Following COVID-19 Vaccination in Systemic Lupus Erythematosus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDisease flare after COVID-19 vaccination is a major concern among patients with systemic lupus erythematosus (SLE) and may contribute to vaccine hesitancy. We evaluated patient-reported flare symptoms, associated factors, and adverse events following COVID-19 vaccination in patients with SLE.
methodsWe conducted a cross-sectional study of adult patients with SLE who received at least one COVID-19 vaccine dose. Demographic data, disease activity, treatments, and patient-reported flare symptoms occurring within four weeks after vaccination were collected.
resultsA total of 324 patients were included; 94.4% were women with a mean age of 40.8 ± 11.7 years. Most patients received at least two vaccine doses (92.0%), and 66.0% received three doses. Patient-reported flare symptoms occurred in 17.0% of patients. The most common manifestations were joint pain, fatigue, hair loss, and myalgia. Most patient-reported flares were mild, though 9% required hospitalization. Current prednisolone use was associated with patient-reported flare symptoms (p = 0.049), though this borderline association should be interpreted cautiously. Vaccine type and baseline disease activity were not associated with patient-reported flare.
conclusionsPatient-reported flare symptoms following COVID-19 vaccination were generally mild in this SLE cohort. Vaccine type was not associated with patient-reported flare symptoms, supporting the overall tolerability of repeated COVID-19 vaccination in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.